Document:

License and Distribution Agreement

 Exhibit 10.17 
 CONFIDENTIAL 
 GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT

 This GALECTIN -3 LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”), entered into as of December 14, 2010
(the “Effective Date”), by and between Siemens Healthcare Diagnostics Inc, a corporation of the state of California, having its principal place of business at 511 Benedict Avenue, Tarrytown, NY 10591 (“SIEMENS”) and
BG Medicine, Inc., a corporation of the state of Delaware, having its principal place of business at 610N Lincoln Street, Waltham, MA 02451 (“BGM”). 
 WITNESSETH: 
 WHEREAS, SIEMENS desires to develop, manufacture and
market Products (as such term is defined and herein) for use on the Siemens Instruments in the Territory (as hereinafter defined); 
 WHEREAS, SIEMENS desires to promote and market Products in the Territory (as hereinafter defined); 
 WHEREAS, BGM owns or otherwise controls or has rights to certain intellectual property rights which may cover Products (“Patent Rights” as hereinafter defined); 

WHEREAS, BGM desires to grant to SIEMENS under Patent Rights a license to make, have made, use, offer for sale, sell, have sold, import,
distribute and have distributed Products in the Territory; and 
 WHEREAS, SIEMENS desires to obtain such license. 

NOW, THEREFORE, in consideration of the mutual covenants and agreement contained herein, and upon the terms and subject to the conditions
set forth below, SIEMENS and BGM hereby agree as follows: 
 ARTICLE 1. DEFINITIONS 

 

	1.1	“Affiliate” means, with respect to any Party (as hereinafter defined), any entity which controls, is controlled by or is under common control with,
such Party. As used herein, the term “control” means with respect to any entity, the power to direct or cause the direction of the management and policies of that entity, whether directly or indirectly and whether through ownership of more
than fifty percent (50%) of the outstanding voting stock or equity of an entity, by contract or otherwise. 

  

	1.2	“Average Selling Price,” or “AUP,” is the average price per test of Product sold to end users in a specified territory as reported by
an independent pricing survey for one or more Calendar Quarters. AUP shall be determined on a Product by Product basis, and in no event shall the average price of a Test for use in a Panel (as defined below) be included in the calculation of AUP for
any Product that is not a Test for use in a Panel. 

  
 1 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	1.2	“Calendar Quarter” means a period of three (3) consecutive calendar months of a calendar year, beginning on
January 1, April 1, July 1 or October 1. 

  

	1.3	“Change of Control” means: (a) the consolidation or merger of BGM with or into any Third Party wherein the shareholders of BGM immediately prior
to such transaction shall cease to be the holders of at least fifty percent (50%) of the outstanding securities of the surviving corporation in such transaction; (b) the assignment, sale, transfer, lease or other disposition of all or
substantially all of the assets of BGM relating to the business to which this Agreement relates; or (c) the acquisition by any Third Party or group of Third Parties acting in concert, of beneficial ownership (within the meaning of Rule 13d-3 of
the Securities and Exchange Commission (“SEC”) under the Securities and Exchange Act of 1934) of more than fifty percent (50%) of the outstanding shares of voting stock of BGM. 

 

	1.4	“Commercially Reasonable Efforts” shall mean those efforts in accordance with the subject Party’s efforts and resources normally used by it for a
product owned by it, or to which it has rights, which is of similar market potential at a similar stage in its product life, taking into account the competitiveness of the marketplace, the proprietary position of the product, the regulatory
structure involved, the profitability of the applicable product, and other relevant factors including technical, legal, scientific or medical factors. 

  

	1.5	“Confidential Information” means any proprietary, confidential, non-public information, data, samples, plans, marketing plans, reports, forecasts,
formulae, processes, technical or commercial information, trade secrets, patent applications, improvements, invention disclosures or know-how disclosed in writing by one Party to another Party under this Agreement, as well as information disclosed
in any other form and identified as “Confidential Information” at the time of disclosure, to the extent such disclosure is reduced to writing, marked “Confidential” and provided to the receiving Party within thirty (30) days
after oral disclosure. 

  

	1.6	“First Commercial Sale” means the date on which SIEMENS (or its Affiliate or agent) first sells a Product to a Third Party in the Territory for
monetary consideration. 

  

	1.7	“Galectin-3” means the soluble galactoside-binding protein coded by the LGALS3 gene. 

 

	1.8	“Knowledge” means, with respect to BGM, the actual knowledge, after due inquiry, of the chief executive officer or any executive officer (as defined
for purposes of Section 14 of the Securities Exchange Act of 1934, as amended) of BGM, 

  

	1.9	“Party” means SIEMENS or BGM and “Parties” means SIEMENS and BGM. 

 

	1.10	 “Patent Rights” means (a) the patents and patent applications listed on Exhibit 1.12 and: (b) all patents and patent
applications owned or controlled by BGM during the Term of the Agreement relating to Galectin-3 or Products; (c) the patents or patent applications acquired by BGM during the Term of this Agreement relating to Galectin-3 or Products;
(d) all patents or patent applications covering Galectin-3 or Products under which BGM becomes licensed and has the right to sublicense; (e) all patents arising from applications

  
 2 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	 
identified in (a), (b), (c) or (d); (f) any extension, renewal or reissue of a patent identified in (a), (b), (c), (d) or (e); (g) any and all foreign counterparts or
equivalents issued of any patents identified in (a) through (e); and (h) any reexamination or renewal of a patent identified in (a) through (e). 

 

	1.11	“Product(s)” means individually and collectively Galectin-3 assay kits, Galectin-3 control kits and Galectin-3 calibrator, the manufacture, use or sale
of which would, but for the licenses granted herein, infringe a Valid Claim. 

  

	1.12	“Steering Committee” means a committee of individuals from the Parties which shall meet on a regular basis as the Parties require, which shall be
composed of equal numbers of individuals from each Party. The Steering Committee shall review Product development, Galectin-3 marker development, clinical studies and any other relevant issue regarding the Product that comes up during the Term.

  

	1.13	“Term” has the meaning set forth in Section 11.1. 

 

	1.14	“Territory” means every country in the world. 

  

	1.15	“Test” means an individual Galectin-3 assay test for a single determination of Galectin-3, the manufacture, use or sale of which would, but for the
licenses granted herein, infringe a Valid Claim; provided that a Test does not include tests used for purposes of Galectin-3 controls,Galectin-3 calibrators, or no-charge promotional sample kits. 

 

	1.16	“Third Party” means a person or entity other than SIEMENS, BGM or any of each Party’s Affiliates. 

 

	1.17	“Valid Claim” means any claim of an issued and unexpired patent within Patent Rights that is applicable with respect to a Product, which claim has not
been held invalid or unenforceable by a decision of a court or governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal or which has not been admitted by the patentee to be invalid or unenforceable
through reissue, disclaimer or otherwise. In the event a patent has been held to be invalid or unenforceable, and an appeal is pending, such claims shall not be considered a Valid Claim until reinstated by a final decision, not subject to further
appeal, of a court or governmental agency of competent jurisdiction; provided, however, that once reinstated, a Valid Claim shall be considered a Valid Claim retroactively as if the patent had never been held to be invalid or
unenforceable. 

  

	1.18	“Cell Lines” means those cell lines owned or controlled by BGM that produce monoclonal antibodies to galectin-3 designated as TIB-166.

  

	1.19	“Antibodies” means monoclonal antibodies generated from Cell Lines that specifically bind to galectin-3. 

 

	1.20	“Know-How” means that confidential information provided by Licensor to Licensee in writing which is used by Licensee in the manufacture of Products.

  
 3 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 2. GRANT OF LICENSES 

 

	2.1	License Grant. BGM hereby grants to SIEMENS and its Affiliates a royalty-bearing license under Patent Rights to make, have made, develop, have developed, use,
offer for sale, sell, have sold, import, distribute and have distributed Products in the Territory. Products may be commercialized only under the names and brands of SIEMENS and its Affiliates and only for use with platforms or technology owned or
controlled by SIEMENS or its Affiliates. BGM also hereby grants to SIEMENS and its Affiliates a sub-license to use Cell Lines to make Antibodies solely for use in Products or to have such Antibodies made by a third party contract manufacturer and to
use the Know-How to make or have made Products or Antibodies. Such sub-license shall be in accordance with the terms and conditions of the license granted to BGM for use of Cell Lines or Antibodies, without any mark-up by BGM. SIEMENS shall not have
the right to grant a sublicense to any Third Party. 

  

	2.2	Additional Licensees. BGM shall have the right to license Patent Rights to no more than four (4) Third Parties (“Other Licensees,” and
together with SIEMENS, the “BGM Licensees”) for such Other Licensees to make, have made, use, offer for sale, sell, have sold, import, distribute, have distributed a Galectin-3 assay, whether on an automated system or not;
provided, that a) beginning after December 31, 2014, BGM may license Patent Rights to additional Third Parties (who shall then be considered Other Licensees) to offer for sale, sell, have sold, import, distribute or have distributed a
Galectin-3 assay, and (b) no Other Licensee shall receive more favorable financial terms than those set forth in this Agreement. If BGM enters into an arrangement with any Other Licensee for a Galectin-3 assay that would reasonably be believed
to contain more favorable financial terms than those set forth in this Agreement, BGM shall so inform SIEMENS within ten (l0) days of entering such arrangement, and SIEMENS shall be entitled to the benefit of the more favorable financial terms of
such other arrangement from the date of the arrangement with the Other Licensee. In the event SIEMENS deems such Other Licensee’s financial terms to be more favorable and desires to license Patent Rights under such alternative financial terms,
SIEMENS will notify BGM within thirty (30) days of learning of these terms, after which the Parties will develop and execute the necessary amendments to incorporate the more favorable financial terms into this Agreement. Other Licensees shall
not have the right to grant sublicenses to any Third Party. For avoidance of doubt, BGM, Licensee and the Other Licensees shall be free to enter into agreements for development, manufacturing or distribution of their products, and such agreements
shall not be considered licenses to Patent Rights for purposes of this Section 2.2. In addition, the terms of this Section 2.2 are not intended to apply to reductions in fees (marketing, product or otherwise), royalties, charges or other
payments or business terms under agreements with Other Licensees that may occur after the execution of such agreements. Any adjustment in the terms of this Agreement to which SIEMENS shall be entitled as a result of any such reduction shall be
determined in accordance with Section 3.3(a) below. 

  
 4 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	2.3	Updates to Patent Rights. BGM shall be responsible for updating Exhibit 1.12 to include all developments and updates to all patents listed therein and
providing written notice to SIEMENS. SIEMENS shall have no payment obligations pursuant to Section 3.1 or 3.2 with respect to new Patent Rights unless and until BGM notifies SIEMENS, in writing, that new patents have issued and are included
within the Patent Rights. 

 ARTICLE 3. FEES AND PAYMENTS 

 

	3.1	Product Fee (US). SIEMENS shall pay to BGM a fee (the “US Product Fee”) consisting of a product access fee of [***] (US $[***]) and a marketing
service fee of [***] ($[***]) for each Test sold by SIEMENS (or its Affiliate or agent) to a Third Party in the US subject to any reductions as permitted in this Agreement. 

 

	3.2	Product Fee (EU and Rest of the World). SIEMENS shall pay to BGM a fee (the “OUS Product Fee,” with each of the US Product Fee and the OUS
Product Fee being sometimes referred to as a “Product Fee”) consisting of a product access fee of [***] (€[***]) and a marketing service fee of [***] (€[***]) for each Test sold by SIEMENS (or its Affiliate or agent) to a
Third Party in the EU or elsewhere outside the US, subject to any reductions as permitted in this Agreement. 

  

	3.3	Product Fee Reductions. During the term of this Agreement and on a Region by Region basis, SIEMENS shall be entitled to reductions in Product Fees as follows:

 (a) on an annual basis and on a US and OUS basis the proportionate amount of any reduction in fees (marketing,
product or otherwise), royalties, charges or other payments or business terms provided to Abbott or Other Licensees. For example, Abbott Diagnostics, as the initial party to execute a Galectin-3 License and Distribution Agreement for an automated
galectin-3 assay, is entitled to a reduction in the Product Fee paid per Test by Abbott to BGM under certain circumstances, Circumstances that may trigger such Product Fee reduction under the Abbott agreement include: 

(i) Failure to get clinical utility indications for the Test in support of an AUP of at least [***] Dollars (US $[***]); and 

(ii) Fall in AUP of galectin-3 tests sold in the United States below a certain pricing level as evident from an independent pricing study;
or 
 (b) on an annual basis in the event Abbott is no longer a licensee or every five years if Siemens has not obtained
reduction in royalty for the past five years, both on a US and OUS basis, a reduction in Product Fees in the same percentage as the percentage based on any decrease in AUP in a Region as compared to the AUP in that same Region as of the date of any
last Product Fee reduction, provided that the decrease in ASP must be at least [***] percent ([***]%) from the AUP as of the date of the last Product Fee adjustment. 
 If the Parties are unable to agree on the amount of the reduction of the Product Fee, the matter shall be resolved by the Alternative Dispute Resolution process set forth in Section 12.12 and Exhibit
12.12. 

  
 5 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 For purposes of this agreement the term Region means the following regions of the world:
Japan, EU, United States, Canada and Rest of World. 
  

	3.4	Product Fee for Inclusion in Panel. In the event SIEMENS sells any Test as part of a panel of tests for a point of care platform to detect Galectin-3 and one or
more other markers indicated for use in heart failure, then if such panel has an [***] price of at least [***] dollars ($[***]), or the equivalent thereof in local currency at the time of sale, and all tests in such Panel are accomplished in a
single step with a single cartridge or set of reagents (a “Panel”), then the Product Fee for Tests shall be [***] dollars ($[***]) per test. If the specific conditions for such panel are not met, the Product Fee set forth in
Section 3.1 or 3.2 shall apply. 

  

	3.5	Product Fee Payable Only Once. The Product Fee set forth in Section 3.1, 3.2 and 3.4 shall be payable hereunder only once with respect to a Test, regardless
of the number of patents set forth in Patent Rights that cover Products. 

  

	3.6	Reductions to Fees Due to Third Party Licenses. SIEMENS, in its sole discretion, may determine that additional royalty-bearing licenses are required from Third
Parties in order to make, have made, use, offer for sale, sell, have sold, import, distribute, have distributed Products in the Territory. If SIEMENS so determines that such licenses are required specifically to make, have made, use, offer for sale,
sell, have sold, import, distribute, or have distributed Product or indications for Product in the Territory, SIEMENS shall notify BGM within[***] ([***]) [***] of making such determination. After notification BGM will attempt to resolve the matter
in a timely manner and to SIEMENS’ satisfaction. However, if SIEMENS, at any time, in its sole discretion, determines that such license is required [***] and [***] obtains the additional royalty-bearing licenses, SIEMENS has the right to deduct
the royalties actually paid to such Third Parties from the fees payable to BGM; provided, that such deduction shall not be for more than [***] percent ([***]%) of the amounts otherwise due and payable to BGM hereunder. If Siemens elects to use the
M3/38 Antibodies derived from the ATCC cell lines subject to the BGM ATCC licensing agreement, the royalties owed to ATCC under that agreement qualify in accordance with this Section 3.6 for the deduction from Product Fees payable to BGM.

  

	3.7	Payments. All payments shall be made quarterly. SIEMENS shall pay BGM within thirty (30) days of the end of the Calendar Quarter during which sales
occurred. 

  

	3.8	Product Fee Reports. Within thirty (30) days of the end of each Calendar Quarter during which sales occurred, SIEMENS shall deliver to BGM a report
describing on either a country-by-country or territory-by-territory basis, at the discretion of SIEMENS, the number of Tests sold by SIEMENS and its Affiliates. 

 

	3.9	Currency Conversion. All payments made hereunder shall be in US Dollars. 

 

	3.10	Transfer of Payments. All payments due and payable hereunder to BGM shall be made by wire transfer to the following bank account number or such other bank or
other location as may be designated in writing by BGM from time to time: 

 Wire Transfer Information: 

Bank Name: [***] 

Bank Address: [***] 
 Account Number: [***] 
 Swift Code: [***] 

  
 6 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	3.11	Tax Withholding. Insofar as any fees that are due to BGM under this Agreement with respect to sales of Products outside the United States are subject to taxation
where the taxes are imposed on SIEMENS, BGM shall bear all such taxes. BGM hereby authorizes SIEMENS to withhold such taxes from the payments that are payable to BGM hereunder if SIEMENS is either: (a) required to do so under the tax laws of
the country of sale or its country of incorporation; or (b) directed to do so by an agency of such government. SIEMENS shall provide BGM with the best available evidence of payment whenever SIEMENS deducts such taxes from any payment due BGM.
Where any sum due to be paid to BGM is subject to any withholding or similar tax, the Parties shall use Commercially Reasonable Efforts to do all such acts and things and to sign all such documents as will enable them to take advantage of any
applicable double taxation or tax reduction agreement or treaty. If there is no applicable double taxation or tax reduction agreement or treaty, or if an applicable double taxation or tax reduction agreement or treaty reduces but does not eliminate
such withholding or similar tax, SIEMENS or its Affiliates shall pay such withholding or similar tax to the appropriate government authority, deduct the amount so paid from the amount otherwise due and payable to BGM, and secure and send to BGM the
available evidence of such payment. 

  

	3.12	Record Keeping; Audits. SIEMENS shall keep full and accurate accounting records of all Tests sold in sufficient detail to determine the Product Fees payable by
SIEMENS to BGM. Upon reasonable written notice to SIEMENS, BGM shall have the right, during normal business hours, to have an independent certified public accountant, selected by BGM and acceptable to SIEMENS, audit SIEMENS’ records pertaining
to the number of Tests sold on a confidential basis to verify the Product Fees payable pursuant to this Agreement; provided, however, that such audit shall not: (a) take place more frequently than [***] per [***]; and
(b) cover records for more than the preceding [***] ([***]) [***]. Such certified public accountant shall enter into a non-disclosure agreement with confidentiality provisions at least as stringent as those set forth in this Agreement, and
shall only disclose the conclusion of such audit to BGM and SIEMENS, and not any of SIEMENS’ customers, pricing or other Confidential Information. The results of such audit shall be[***]. Any adjustment in payment shall be made upon
demonstration of any underpayment or overpayment. 

  

	3.13	Cost of Audits. All fees and expenses of any audit requested by BGM pursuant to Subsection 3.12 shall be borne by BGM; provided, however,
that if any audit reveals that SIEMENS underpaid Product Fees due to BGM under this Agreement as to the time period being audited by more than [***] percent ([***]%) of the amount that was payable for such time period, and as long as the
underpayment amount is at least [***] ($[***]), SIEMENS, in addition to paying BGM any underpayment, shall reimburse BGM for the cost of such audit. 

  
 7 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 4. GALECTIN-3 DEVELOPMENT AND PROMOTIONAL ACTIVITIES 

 

	4.1	Transfer of Cell Line. Within thirty (30) days after the Effective Date, BGM shall provide a minimum of five (5) frozen vials of each Cell Line to
SIEMENS of sufficient quality and viability for SIEMENS to make, have made, use and reproduce and have reproduced Cell Line and to possess, culture and employ Cell Line to produce and characterize Antibodies and to use Antibodies to develop,
release, characterize or manufacture Product, including without limitation test, release, characterize or manufacture commercial quantities of Product, and shall include all documentation on Cell Line and Antibodies in accordance with the procedures
described in this Agreement as well as in the specifications set forth in Exhibit B. BGM shall select a qualified employee who shall act as its technical correspondent in transferring Cell Lines and in transmitting such documentation. SIEMENS shall
select a qualified employee who shall receive such Cell Line and documentation. In addition BGM shall, upon SIEMENS’ reasonable request, provide all reasonable training and assistance, under conditions to be mutually agreed between the Parties
hereto. 

  

	4.2	SIEMENS shall provide BGM with written notice of successful establishment of the Cell Lines within ninety (90) days of the date of delivery of the Cell Lines.
Successful transfer of Cell Line to SIEMENS under Section 4.1 shall be made within ninety (90) days of delivery of the Cell Lines and determined by establishment of Cell Lines sat SIEMENS or SIEMENS designated contractor, in accordance
with the following criteria: 

  

	 	(a)	Cell Lines are free of bacteria, mycoplasma, viral and fungal contamination upon receipt at SIEMENS facility or its designated Contractor’s facility;

  

	 	(b)	Cell Lines are viable, as determined by stabilization and production of Antibodies consistent with the specifications; and 

 

	 	(c)	Cell Lines produces Antibodies which bind specifically to galectin-3. 

  

	4.3	At the reasonable request of SIEMENS, BGM shall prepare and promptly provide necessary information relating to the Cell Lines or Antibodies as is required to support
filings by SIEMENS or its Affiliates for the registrations for Products and shall use Commercially Reasonable Efforts to cooperate as required in resolving regulatory concerns that arise with respect to the use of the Cell Lines or Antibodies in the
development and manufacture of Product. In addition, BGM shall provide to SIEMENS the right to reference relevant portions of BGM’s regulatory filings and/or all authorizations, certificates, methodologies and specifications in the possession
or under the control of BGM relating to the Cell Lines and/or Antibodies to the extent available and needed for SIEMENS’ filings. 

  

	4.4	If within the ninety (90) day period after delivery of the Cell Line the initial establishment of the Cell Line delivered to SIEMENS is unsuccessful, as determined
solely by SIEMENS, BGM shall continue to assist SIEMENS to establish the Cell Line. 

  

	4.5	 SIEMENS’ Development Efforts. During the Term of this Agreement, SIEMENS shall use Commercially Reasonably Efforts to develop, test and
submit an application to obtain regulatory approval to sell Products throughout the Territory, but in any event in the 

  
 8 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
United States and the European Union. Without limiting the generality of the foregoing, SIEMENS intends to initially develop a Product for use on its ADVIA CENTAUR® laboratory systems, and thereafter may develop Products for use on other diagnostic platforms owned or controlled by
SIEMENS and sold under trademarks of SIEMENS. The Parties will develop a development plan and non-binding timeline for such development as set forth in Exhibit 7.1. 
 SIEMENS agrees that it will [***] for any [***] in any jurisdiction unless and until it has [***] for a [***] in such jurisdiction and launched such Product in such jurisdiction. 

 

	4.6	SIEMENS’ Sales Efforts. During the Term of this Agreement, SIEMENS shall use Commercially Reasonable Efforts to promote, market, sell and distribute
Products throughout the Territory. Such efforts may include preparing collateral marketing materials, conducting advertising, presenting educational seminars, detailing, displaying exhibits at trade shows and ensuring representation and attendance
at industry meetings, all of which shall be performed in accordance with SIEMENS’ usual and customary practices that SIEMENS would use for SIEMENS’ products of a similar nature. SIEMENS solely shall be responsible for the costs incurred in
such efforts hereunder. As part of its promotion and marketing efforts, SIEMENS may elect to offer Products to potential customers at no charge for evaluation purposes, which Products shall not be subject to Section 3.1, 3.2 or reported
pursuant to Section 3.8. 

  

	4.7	Selling Price. SIEMENS, in its sole discretion, shall determine the final sales price of Products sold by SIEMENS to Third Parties in the Territory, and no other
term or provision of this Agreement shall be interpreted or deemed to provide BGM with any right to determine or influence the final sales price of Products sold by SIEMENS hereunder. 

 

	4.8	Development of Promotional and Marketing Materials for Products. Promptly following the Effective Date, BGM shall deliver to SIEMENS copies of any promotional
marketing materials owned or controlled by BGM that may be used by SIEMENS in the promotion and sale of Products. BGM represents and warrants that the statements made in any promotional marketing materials owned or controlled by and provided to
SIEMENS shall be accurate and complete in all material respects. SIEMENS also shall have the right to develop and prepare, at SIEMENS’ sole discretion and at its own cost, promotional and marketing materials for use in its sale and distribution
of Products. SIEMENS shall be responsible for the accuracy of all statements made in all materials developed by SIEMENS. 

  

	4.9	Steering Committee Meetings. The Steering Committee shall meet no less frequently than quarterly to review the progress of the development of Products by
SIEMENS, the activities of described in Section 5.1, any Product Inventions or Indication Inventions of either Party, and such other topics related to Galectin-3 or Products as either Party may request. 

 

	4.10	Exclusivity. During the Term. SIEMENS shall not develop, manufacture or commercialize a Galectin-3 assay other than Product if such other assay would fall within
the claims in the patents included in the Patent Rights and for so long as BGM holds all Patent Rights and intellectual property necessary to sell Products subject to these claims. 

  
 9 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	4.11	No Excluded Parties. During the Term, SIEMENS shall not deny the sale or supply of Product to any laboratory service provider meeting standard or customary
SIEMENS customer criteria and willing to purchase Product on standard terms. 

 ARTICLE 5. CLINICAL STUDIES
AND CLINICAL INDICATIONS 
  

	5.1	Clinical Studies and Clinical Indications. BGM shall use Commercially Reasonable Efforts to validate the clinical use of Galectin-3 as described on Exhibit
5.1 and any amendments added to Exhibit 5.1 by mutual written agreement of the Parties. The Parties shall discuss the protocols, intended use objectives, status, results and opportunities for expanded clinical claims for the Products
during the quarterly Steering Committee meetings. 

 ARTICLE 6. INTELLECTUAL PROPERTY 

 

	6.1	Inventions Covering Product. BGM shall own all right, title and interest in and to all inventions during the Term specifically covering the Cell Lines and the
Antibodies used in the Product (“Product Inventions”) and inventions covering indications for the use of Galectin-3 (“Indication Inventions”), conceived and reduced to practice solely by BGM. If Product Inventions
or Indication Inventions are conceived and reduced to practice hereunder jointly by SIEMENS and BGM (“Joint Inventions”) US inventorship laws shall govern the ownership of such Joint Inventions. All Product Inventions and Indication
Inventions hereunder owned or controlled by BGM during the Term shall become part of Patent Rights hereunder. 

  

	6.2	SIEMENS’ Galectin-3 Intellectual Property. If SIEMENS solely conceives and reduces to practice any new Product Inventions or Indication Inventions that
result in new patents being sought to cover such new reagents or indications, SIEMENS shall own such Product Inventions and Indication Inventions, and shall make such Product Inventions and Indication Inventions available to BGM and the Other
Licensees on a non-exclusive, royalty-free basis during the Term strictly for use related to Product(s) provided the foregoing only applies to such Other Licenses who have agreed to make their Product Inventions and Indication Inventions available
to SIEMENS on a non-exclusive and royalty-free basis. SIEMENS, in its sole discretion and for its own benefit, shall have the right to exploit such SIEMENS-owned Product Inventions and Indication Inventions in the Territory.

  

	6.3	BGM Licensee Galectin-3 Intellectual Property. BGM shall use Commercially Reasonable Efforts to contractually require of each Other Licensee that if an Other
Licensee conceives, reduces to practice, owns controls (through sublicensing or otherwise) any new Product Inventions or Indication Inventions pertaining to Products that are patented or that result in new patents being sought, then SIEMENS shall be
granted a non-exclusive, royalty-free license, during the Term, to make, have made, use, offer for sale, sell, have sold, import, distribute and have distributed Products using such new Product Inventions or Indication Inventions.

  
 10 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	6.4	Patent Prosecution. Each Party shall be solely responsible for the filing and prosecution of patent applications claiming inventions owned by such Party. Unless
otherwise agreed by the Parties, the Parties will jointly file and prosecute patent applications for Joint Inventions. 

 ARTICLE 7. INFRINGEMENT AND ENFORCEMENT 
  

	7.1	Patent Enforcement. 

  

	 	7.1.1	Notice and Investigation of Infringement. Each Party shall promptly notify the other Party of any possible infringement of BGM’s patents included in Patent
Rights by a Third Party of which such Party has knowledge. BGM shall promptly investigate such possible Third Party infringement and shall inform SIEMENS of its findings with respect thereto within thirty (30) days of such notice, or such
longer period as is required to determine if infringement is occurring. 

  

	 	7.1.2	BGM Actions and Participation. During the Term, BGM shall have the right, but not the obligation, to enforce any and all claims of infringement of any BGM
patents included in Patent Rights and any patents claiming a Joint Invention or any related proprietary rights, in its own name, at its own expense and for its own benefit, and SIEMENS shall take reasonable actions to enable BGM to enforce such
action in BGM’s own name, including, but not limited to, the execution of any necessary papers. SIEMENS shall join BGM as a party to such prosecution if it is reasonably determined by BGM that SIEMENS is a necessary party to such prosecution,
whereupon BGM shall bear all costs and control such litigation as if such action had been brought solely in BGM’s name. BGM shall have the right to control all aspects of the enforcement of any claim against a Third Party brought pursuant to
the provisions of this Subsection 7.1.2, including, but not limited to, the right to: (a) select counsel; (b) establish litigation strategies; and (c) pursue settlement discussions and enter into settlements. SIEMENS shall have
the right, at its option and costs, to join any such action by BGM in order to seek damages the relevant infringement has caused SIEMENS. If within six (6) months of notice by SIEMENS to BGM of suspected infringement, BGM has not either stopped
such infringement, entered into a license with such infringer or caused commencement of litigation against such infringer, SIEMENS’S obligations to pay royalties under this Agreement, shall be reduced by [***] for a period of six
(6) months. If after six (6) additional months BGM has not stopped such infringement, entered into a license with such infringer or caused commencement of litigation against such infringer, SIEMENS’ obligations to pay royalties under
this Agreement shall be suspended and shall not resume in full until such time as BGM has stopped the infringement, licensed the infringer or caused litigation to be brought against the infringer. 

  
 11 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	7.1.3	SIEMENS Action. In the event BGM does not pursue enforcement of any patents claiming a Joint Invention as set forth in Subsection 7.1.2, and SIEMENS
reasonably believes that such infringement shall materially impact SIEMENS’ ability to market the Products, SIEMENS shall have the right, but not the obligation, to enforce any and all claims of infringement of any patents claiming a Joint
Invention against such infringement, in its own name, at its own expense and for its own benefit, and BGM agrees to take all actions reasonably necessary to enable SIEMENS to enforce such action in its own name, including, but not limited to, the
execution of any necessary papers. BGM shall join SIEMENS as a party to such prosecution if it is reasonably determined that BGM is a necessary party to such prosecution, whereupon SIEMENS shall bear all costs and control such litigation as if such
action had been brought solely in SIEMENS’ name. SIEMENS shall have the right to control all aspects of the litigation of any claim against a Third Party brought pursuant to the provisions of this Subsection 7.1.3, including, but not
limited to, the right to: (a) select counsel, such selection to be subject to BGM’s written approval, such approval not to be unreasonably withheld; (b) establish litigation strategies, subject to an obligation to confer with BGM
regarding such strategies and to give reasonable consideration to BGM’s input with respect to such strategies; and (c) pursue settlement discussions and enter into settlements. Notwithstanding the foregoing, SIEMENS shall not settle any
such litigation or claim without the prior written consent of BGM, which consent shall not be withheld unreasonably. 

  

	 	7.1.4	Proceeds Recovered. Any amount received by SIEMENS as a result of any proceeding referred to in Subsection 7.1.3, shall be distributed and paid as
follows: (a) first, to reimburse SIEMENS for all expenses incurred by it in connection with such proceeding; (b) second, to reimburse BGM for any expenses incurred by it in connection with such proceeding; and (c) third, any
additional amounts remaining after such application shall be [***]. 

  

	 	7.1.5	Cooperation. The Party controlling the action shall keep the other Party reasonably informed of the progress of the suit, claim or proceeding.

  

	7.2	Defense of Assertions of Infringement of Third Party Patents 

  

	 	7.2.1	Assertion Against SIEMENS. In the event of a Third Party assertion against SIEMENS of patent infringement (or any other violation of a proprietary right of a
Third Party) related to the manufacture, use or sale of the Product(s) by SIEMENS in the Territory, SIEMENS shall defend such assertion, at its sole discretion and at its sole expense. SIEMENS shall promptly notify BGM in writing of the assertion or
claim, including details and known facts regarding such assertion or claim. BGM shall provide, upon SIEMENS’ request and at SIEMENS’ sole expense, reasonable assistance for such defense. SIEMENS shall have the right to settle such
assertion on terms acceptable to SIEMENS; provided, however, that SIEMENS shall not enter into any settlement that would affect BGM’s Patent Rights relating to Products without the prior, written consent of BGM.

  
 12 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 8. REPRESENTATIONS AND WARRANTIES 

 

	8.1	General Representations and Warranties. Each Party represents and warrants to the other Party as of the Effective Date of this Agreement:

  

	 	(a)	It is a corporation duly organized and validly existing under the laws of its state of incorporation; 

 

	 	(b)	It has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder; 

 

	 	(c)	At no time prior to the termination or expiration of this Agreement, shall BGM enter into any transaction which would prohibit or materially impair BGM from fulfilling
its obligations under this Agreement. 

  

	8.2	Patent Representations and Warranties. BGM represents and warrants to SIEMENS the following as of the Effective Date of this Agreement: 

 

	 	(a)	It is the sole owner of all right, title and interest in and to the patents included in Patent Rights, and no approvals or other documentation are necessary to be
obtained from any Third Party in order for the licenses and rights to be conferred to SIEMENS hereunder; 

  

	 	(b)	There have been no written claims or assertions, or to BGM’s Knowledge any oral claims or assertions, that the making, using, offering for sale, use, or importing
of one or more of the Products infringes the patents or other proprietary right of any Third Party; 

  

	 	(c)	except as set forth on Schedule 8.2, BGM has no Knowledge of any Third Party patents, trademarks or other proprietary rights which would be infringed by making, having
made, using, selling, offering for sale or importing Products in the Territory in accordance with the terms of this Agreement; and 

  

	 	(d)	To its Knowledge, BGM is not, and as a result of the execution and delivery of this Agreement, will not be, in violation of, or lose of any rights pursuant to, any
license, sublicense or agreement previously provided to BGM by a Third Party with respect to Patent Rights relating to Products. 

  

	8.3	Not Inferior Business Terms. BGM represents and warrants to SIEMENS the following as of the Effective Date of this Agreement: 

Subject to the effect of currency fluctuations, it has not granted any license to make, develop or sell a galectin-3 assay for automated
laboratory instruments on substantially superior terms to the terms granted to SIEMENS and that the aggregate of product fees, marketing fees and other licensing fees are comparable to the fees under this agreement ([***]%). 

  
 13 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	8.4	SIEMENS Representations and Warranties. SIEMENS represents and warrants to BGM the following as of the Effective Date of this Agreement:

  

	 	(a)	SIEMENS [***] of any [***] in order to make, have made, use, offer for sale, sell, have sold, import, distribute, have distributed Products in the Territory; and
(b) SIEMENS [***] or [***] related to [***], or [***] to [***] from a [***] to BGM, 

  

	8.5	Debarment and Exclusion. BGM represents and warrants that neither it, nor any of its employees or agents working on the subject matter of this Agreement, has
ever been, is currently, or is the subject of a proceeding that could lead to it becoming, as applicable, a Debarred Entity or Individual, an Excluded Entity or Individual or a Convicted Entity or Individual. BGM further covenants, represents and
warrants that if, during the Term of this Agreement, it, or any of its employees or agents working on SIEMENS’s behalf, becomes or is the subject of a proceeding that could lead to that Party becoming, as applicable, a Debarred Entity or
Individual, an Excluded Entity or Individual or a Convicted Entity or Individual, BGM shall immediately notify SIEMENS, and SIEMENS shall have the right to immediately terminate this Agreement. This provision shall survive termination or expiration
of this Agreement. For purposes of this provision, the following definitions shall apply: 

  

	 	(a)	A “Debarred Individual” is an individual who has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) from providing services
in any capacity to a person that has an approved or pending drug product application. 

  

	 	(b)	A “Debarred Entity” is a corporation, partnership or association that has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or
(b) from submitting or assisting in the submission of any abbreviated drug application, or a subsidiary or Affiliate of a Debarred Entity, 

  

	 	(c)	An “Excluded Individual” or “Excluded Entity” is (i) an individual or entity, as applicable, who has been excluded, debarred,
suspended or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG/HHS) of the U.S. Department of Health and Human Services, or (ii) is an individual or
entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal procurement and non-procurement programs, including those produced by the U.S. General Services Administration (GSA).

  

	 	(d)	A “Convicted Individual” or “Convicted Entity” is an individual or entity, as applicable, who has been convicted of a criminal offense
that falls within the ambit of 42 U.S.C. §1320a — 7(a), but has not yet been excluded, debarred, suspended or otherwise declared ineligible. 

  

	8.6	Limitation on Warranties. NEITHER PARTY MAKES ANY OTHER WARRANTIES OTHER THAN THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, AND EXCEPT AS STATED IN THIS
AGREEMENT, THERE SHALL BE NO IMPLIED OR STATUTORY WARRANTIES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. 

  
 14 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	8.7	Additional Representation and Warranty. Each Party represents and warrants to the other Party as of the Effective Date, that the execution, delivery and
performance by it of this Agreement and its compliance with the terms and provisions thereof does not and will not conflict with or result in a breach of any other agreement or relationship, which breach will materially and adversely affect such
Party’s ability to perform its obligations hereunder. 

 ARTICLE 9. INDEMNIFICATION 

 

	9.1	BGM Indemnification. BGM shall indemnify, defend and hold SIEMENS and its Affiliates and their officers, directors, employees and representatives collectively,
(“SIEMENS Indemnitees”) harmless from and against any and all losses, damages, demands, fees, expenses, fines, penalties and costs (including reasonable attorney’s fees) (hereinafter, “Losses”) to the extent
that such Losses arise out of, relate to or are in connection with claims, causes of action, suits or proceedings of Third Parties (hereinafter “Claims”) resulting from: (a) the material breach of BGM’s warranties,
representations or covenants set forth in this Agreement; (b) gross negligence or willful misconduct on the part of BGM, including its employees, agents or representatives. 

 

	9.2	SIEMENS Indemnification. SIEMENS shall indemnify, defend and hold BGM and its Affiliates and their officers, directors, employees, and representatives
(collectively, “BGM Indemnitees”) harmless from and against any and all Losses, to the extent that such Losses arise out, relate to or are in connection with Claims resulting from: (a) the material breach of SIEMENS’
warranties, representations or covenants set forth in this Agreement; (b) gross negligence or willful misconduct on the part of SIEMENS, including its employees, agents or representatives, or (c) the use, sale or import by SIEMENS or any
of its Affiliates, distributors or agents, of any Product or the use of any Product by or in the diagnosis or treatment of any Third Party. 

  

	9.3	Offsetting Claims. With respect to any Claim for which BGM has an obligation to any SIEMENS Indemnitee pursuant to Section 9.1 and SIEMENS has an obligation
to any BGM Indemnitee pursuant to Section 9.2, each Party shall offset the claims against the other. 

  

	9.4	Cooperation. With respect to any Claim for which a Party seeks indemnification (“Indemnitee”) from any other Party
(“Indemnitor”) under this Article 9, the Indemnitee shall: (a) promptly advise the Indemnitor in writing of any Claim within [***] ([***]) [***] after the Indemnitee received notice of such Claim, or within such period of time
so as not to materially prejudice the right of the Indemnitor with regard to the defense of such Claim (whichever time period is shorter); and (b) assist the Indemnitor and its representatives in the investigation and defense of any Claim for
which indemnification is provided. The Indemnitor shall defend, and control the defense of, any such Claim, and shall not offer to settle, settle or otherwise compromise such Claim without the Indemnitee’s prior written consent (which consent
will not be unreasonably withheld), unless such settlement fully releases the Indemnitee without any liability, loss, cost or obligation, 

  
 15 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	9.5	IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY INDIRECT, SPECIAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES, LOSSES, COSTS OR EXPENSES OF ANY KIND, HOWEVER CAUSED ON ANY
THEORY OF LIABILITY AND WHETHER BASED IN CONTRACT OR TORT (INCLUDING NEGLIGENCE), INCLUDING LOST PROFITS OR REVENUES AND LOSS OF GOODWILL, REGARDLESS OF WHETHER SUCH PARTY KNOWS OR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSSES. THE
PARTIES HEREBY WAIVE THE RIGHT TO PUNITIVE DAMAGES. 

 ARTICLE 10. CONFIDENTIALITY AND PUBLIC ANNOUNCEMENTS

  

	10.1	Confidentiality. The Parties acknowledge and agree that during the Term, each of them and their Affiliates may exchange Confidential Information, and the
disclosure and use of any such Confidential Information shall be governed by the provisions of this Section 10.1. Each Party (“Receiving Party”) shall use the Confidential Information of the other Party (“Disclosing
Party”) only for the purpose of the activities contemplated by this Agreement and shall not disclose such Confidential Information to a Third Party except in accordance with the provisions of this Agreement. The Parties shall ensure that
their Affiliates keep all Confidential Information exchanged hereunder confidential in accordance with the provisions hereof as though the Affiliates were parties hereto. This provision shall remain in effect for a period of [***] ([***]) years
after termination or expiration of this Agreement for all Confidential Information excluding Trade Secrets (as defined in Section 10.2). Trade Secrets shall be kept confidential by the Receiving Party (as defined in Section 10.2 hereof)
according to the terms set forth in Section 10.2. The provisions of this Section 10.1 shall not apply to any information which: 

  

	 	(a)	Is known to the Receiving Party before receipt thereof under this Agreement, as evidenced by the Receiving Party’s written records; 

 

	 	(b)	Is disclosed to the Receiving Party without restriction by a Third Party (as hereinafter defined) that is, to the Receiving Party’s knowledge, not under an
obligation of nondisclosure to the Disclosing Party; 

  

	 	(c)	Is or becomes part of the public domain other than through a breach of this Agreement by the Receiving Party; 

 

	 	(d)	Is independently developed by or for the Receiving Party without use of the Disclosing Party’s Confidential Information, as evidenced by the Receiving Party’s
written records; 

  

	 	(e)	In any case in which it is disclosed by the Receiving Party with the Disclosing 

 Party’s prior written approval; or 

  
 16 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	(f)	In any case in which it is required by law to be disclosed; provided, that in such instance the Receiving Party will provide the Disclosing Party with at least
ten (10) business days notice prior to making the required disclosure (or as much notice as possible if the disclosure is required to be made in less than ten (10) business days) in order to allow the Disclosing Party to review such
disclosure and to take appropriate measures to protect the confidentiality of its Confidential Information; provided further, that to the extent the Disclosing Party is unsuccessful in protecting against disclosure of its Confidential
Information, the Receiving Party shall only disclose such Confidential Information to the minimum extent required to comply with applicable law. 

  

	10.2	Handling of Trade Secrets. During the course of its performance hereunder, a Party (the “Disclosing Party”) may desire or be requested to
disclose Confidential Information to the other Party (the “Receiving Party”), which the Disclosing Party considers a trade secret (“Trade Secret”). In such event, the Disclosing Party first shall inform the
Receiving Party, on a non-confidential basis, of the general nature of the Trade Secret information. The Receiving Party shall have [***] ([***]) [***] to decide whether it wishes to have such Trade Secrets disclosed to it and to inform the
Disclosing Party in writing that it wishes to receive such a disclosure. Any Trade Secrets so disclosed between the Parties shall be marked “Trade Secret,” and the Receiving Party shall not disclose or use such Trade Secret for the Term
and thereafter except as expressly permitted under this Agreement. In the event the Disclosing Party discloses the Trade Secrets to the Receiving Party without written approval of the Receiving Party and/or without appropriately marking such
information as “Trade Secret” that trade secret shall be handled as Confidential Information under Section 10.1. 

  

	10.3	Confidential Treatment. Each Party shall seek confidential treatment for the terms and conditions of this Agreement to the fullest extent permitted by the SEC
and any other governmental agency or self-regulatory organization to which a Party provides a copy of this Agreement. Prior to seeking confidential treatment from the SEC or any other governmental agency or self-regulatory organization for any such
document, the filing Party shall provide the other Party and the other Party’s counsel with a copy of the proposed filing showing the filing Party’s proposed redactions of the document, and shall consult with the other Party and the other
Party’s counsel and provide them with a reasonable opportunity to request the inclusion of specified provisions or redactions in any request for confidential treatment. 

 

	10.4	 Permitted Disclosure. Notwithstanding Section 10.1, disclosure of the Disclosing Party’s Confidential Information and of this
Agreement and the terms hereof may be made by the Receiving Party: (I) (a) on a need-to-know basis to the Receiving Party’s legal and financial advisors; (b) as reasonably necessary in connection with an actual or potential
(i) debt or equity financing of the Receiving Party or (ii) Change of Control involving the Receiving Party; and (c) to any Third Party to enable the Receiving Party to exercise its rights and perform its obligations under this
Agreement; if, in the case of clauses (a) (except with respect to disclosures to the Receiving Party’s legal advisors), (b) and (c), the person or entity receiving such Confidential Information of the Disclosing Party is bound by
written or professional obligations substantially as restrictive as those contained 

  
 17 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	 
in Section 10.1, and (II) as reasonably necessary for the Receiving Party to file, prosecute and maintain Patent Rights, or to file, prosecute or defend litigation against Third Parties
related to Patent Rights, in accordance with this Agreement; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available.

  

	10.5	Press Announcements. The terms of this Agreement shall be considered Confidential Information. As soon as reasonably practicable after the Effective Date, the
Parties shall issue a joint public announcement of the execution of this Agreement in a form agreed upon by the Parties and approved through their respective corporate approval processes. Neither Party shall make any public announcement concerning
this Agreement, nor make any public statement which includes the name of any other Party or any of its Affiliates, or otherwise use the name of any of the other Parties or any of their Affiliates in any public statement or document, except as may be
required by law or judicial order, without the written consent of each of the other Parties, which written consent shall not be withheld unreasonably. Once a Party has consented to public disclosure of its Confidential Information pursuant to this
Section 10.5, the other Party may make subsequent public disclosures of the same Confidential Information without further consent. 

 ARTICLE 11. TERM AND TERMINATION 
  

	11.1	Term; Termination for Breach. This Agreement shall commence on the Effective Date, and unless terminated early pursuant to the provisions of this Agreement,
shall expire on the expiration date of the last-to-expire patent in Patent Rights that covers Product (“Term”). Either Party may terminate this Agreement upon sixty (60) days written notice to the other Party if the other Party
materially breaches this Agreement and such breach is not cured within such sixty (60) day period. 

  

	11.2	SIEMENS Termination. SIEMENS shall have the right to terminate this Agreement on thirty (30) days written notice to BGM without further payments due to BGM,
other than payment obligations that have accrued prior to termination, if SIEMENS determines that any of the following occurs: 

  

	 	(a)	BGM is under government or other regulatory restrictions /compliance restrictions relating to Product, or 

 

	 	(b)	SIEMENS is aware of possible infringement by Product of Third Party patents or has been contacted by a Third Party regarding patent infringement relating to Product, or

  

	 	(c)	The predicate device (microplate) does not get regulatory clearance in the US by December 31, 2010, or 

 

	 	(d)	A new marker shows superior clinical utility and is adopted by the physician community. 

  
 18 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	11.3	Consequences of Termination. If SIEMENS, in its sole discretion, voluntarily, and for reasons within its control (i.e., for reasons other than those set forth in
Section 11.2), discontinues the Product’s development program, or discontinues the sale of Products as contemplated by this Agreement, then SIEMENS may terminate this Agreement upon thirty (30) days written notice to BGM, in which
event SIEMENS shall allow BGM to sell Products designed for use on SIEMENS diagnostic systems pursuant to the terms and conditions of a distribution arrangement negotiated in good faith between the Parties, including fair compensation for
SIEMENS’ R&D investments. 

  

	11.4	Accrued Rights and Obligations. The termination or expiration of this Agreement shall not relieve any Party of any obligation arising under this Agreement which
shall have accrued prior to such expiration or termination. 

  

	11.5	Survival. The following Articles and Sections shall survive the expiration or termination of this Agreement: Articles 1, 8, 9, 10 and 11 and Sections 3.10, 3.11,
3.12, 3.13, 6.1, 6.2, 6.4, 7.1.4, 7.1.5 and 7.2. All provisions that survive termination, that are irrevocable or that arise due to termination shall survive in accordance with their terms. Any provisions of this Agreement contemplated by their
terms to pertain to a period of time following termination or expiration of this Agreement shall survive only for the specified period of time. 

 ARTICLE 12. MISCELLANEOUS 
  

	12.1	Force Majeure. No Party shall be liable for loss, damage, detention or delay resulting from any cause whatsoever beyond its reasonable control or resulting from
a force majeure, including, without limitation, fire, flood, strike, lockout, civil or military authority, insurrection, war, embargo, container or transportation shortage or delay of suppliers, and delivery dates shall be extended to the extent of
any delays resulting from the foregoing or similar causes. The Party so affected shall give prompt notice to the other Party of such cause, and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as
reasonably possible. The party giving such notice shall be excused from such of its obligations hereunder for so long as it is so disabled or for thirty (30) days after notification to the other Party, whichever is longer; provided,
however, that such affected Party commences and continues to take reasonable and diligent actions to cure such cause. Notwithstanding the foregoing, nothing in this Section 12.1 shall excuse the obligation to make any payment due
hereunder in the manner and time provided. 

  

	12.2	Assignment. No Party hereto shall have the right to assign any of its rights or obligations under this Agreement to a Third Party without the prior written
consent of each of the other Party, which consent shall not be withheld unreasonably; provided, however, that without such consent, a Party may assign this Agreement in whole or in part to an Affiliate of the assigning Party or in
whole, but not in part, to any purchaser of all or substantially all of its assets to which this Agreement relates or to any successor corporation resulting from any Change of Control. 

  
 19 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	12.3	Binding Effect. This Agreement shall be binding upon and inure to the benefit of each Party hereto and its successors and assigns. 

 

	12.4	Relationship of the Parties. The relationship of the Parties hereunder is that of independent contractors. Nothing contained in this Agreement shall be construed
so as to constitute the Parties as partners, joint ventures or agents of the other. No Party or its Affiliates has any express or implied right or authority under this Agreement to assume or create any obligations or make any representations or
warranties on behalf of or in the name of the other Party or any of such other Party’s Affiliates. 

  

	12.5	Amendments. Except as otherwise expressly provided herein, neither this Agreement nor any provision hereof may be amended except by a written instrument signed
by each Party. 

  

	12.6	Waivers. Any waiver by any Party hereto of any rights arising from a breach of any covenants or conditions of this Agreement shall not be construed as a
continuing waiver of other breaches of the same nature or other covenants or conditions of this Agreement. 

  

	12.7	Notices. All written notices and other communications between the Parties which shall or may be given pursuant to this Agreement shall be deemed to have been
sufficiently given when delivered by personal service or sent by registered or certified mail return receipt requested, overnight delivery service providing evidence of delivery, or confirmed facsimile, to the recipient addressed as follows:

 If to SIEMENS: 
 Siemens Healthcare Diagnostics Inc., 
 511 Benedict Avenue 

Tarrytown, NY 10591 
 Tel: [***] 
 Fax: [***] 

Attn: [***] 

If to BGM: 

BG Medicine, Inc. 

610 Lincoln Street North 
 Waltham, MA 02451 
 Tel: 781-890-1199 

Fax: 781-895-1119 

Attn: President & CEO 
 All such communications shall be deemed to be effective on the day on which personally served, or, if sent by registered mail, on the fourth day following the date presented to the postal authorities for
delivery to the other Party (the cancellation date stamped on the delivery or the envelope being evidence of the date of such delivery), or if by overnight delivery or facsimile, on the delivery or the facsimile date. Either Party may give to the
other Party written notice of change of address, in which event any communication shall thereafter be given to such other Party as above provided at such changed address. 

  
 20 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	12.8	Applicable Legal Requirements. Each Party shall comply with all applicable legal requirements and shall not be required to perform or omit to perform any act
required or permitted under this Agreement if such performance or omission would violate the provisions of any such applicable legal requirement. 

  

	12.9	Further Assurances. Subject to the terms and conditions of this Agreement, each Party shall cooperate with the other Party to take, or cause to be taken, all
actions and to do, or cause to be done, all things necessary or desirable under applicable laws and regulations to consummate the transactions contemplated by this Agreement. 

 

	12.10	Entire Agreement; Conflict in Terms. This Agreement is the sole understanding and agreement between the Parties hereto with respect to the subject matter hereof
and supersedes all other prior agreements and understandings with respect to the subject matter hereof. 

  

	12.11	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, excluding its conflict of laws provisions.

  

	12.12	Alternative Dispute Resolution. Any dispute or claim arising out of or in connection with this Agreement (unless otherwise set forth herein) shall be finally
settled by Alternative Dispute Resolution (“ADR”) in accordance with the process set forth on Exhibit 12.12. 

  

	12.13	Interpretation. Where the context hereto requires, the singular number shall be deemed to include the plural and vice-versa. The headings of the Articles,
Sections and Subsections of this Agreement have been added for the convenience of the Parties and shall not be deemed a part hereof or used in the interpretation of this Agreement. In any context herein, “or” is not exclusive;
“including” and “include” are not exclusive and are deemed to be followed by the words “without limitation.” 

  

	12.14	Severability. If any provision of this Agreement is finally held to be invalid, illegal or unenforceable by a court or agency of competent jurisdiction, that
provision shall be severed or shall be modified by the Parties so as to be legally enforceable (and to the extent modified, it shall be modified so as to reflect, to the extent possible, the intent of the Parties) and the validity, legality and
enforceability of the remaining provisions shall not be affected or impaired in any way. 

  

	12.15	Counterparts. This Agreement may be executed in two (2) original counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument, 

  

	12.16	Mutual Drafting. This Agreement is the joint product of the Parties, and each provision hereof has been subject to the mutual consultation, negotiation and
agreement of the Parties and each Party’s respective legal counsel and advisors, and any rule of construction that a document shall be interpreted or construed against the drafting Party shall not be applicable with respect to this Agreement.

  
 21 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	12.17	Change of Control. In the event of a Change of Control, BGM shall assign all of its obligations under this Agreement to the surviving entity in any merger or
consolidation or to any entity to which it transfers all or substantially all of its business to which this Agreement relates. By such assignment, the acquirer shall be bound by all the terms and provisions of this Agreement, and the acquirer shall
assume all the obligations of BGM under this Agreement. 

 (Remainder of Page Intentionally Left Blank)

  
 22 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be executed by its duly
authorized representative. 
  

									
	SIEMENS HEALTHCARE DIAGNOSTICS INC	 		 	BG MEDICINE, INC.
					
	By:	 	 /s/ David Hickey
	 		 	By:	 	 /s/ Pieter Muntendam

		 	David Hickey	 		 		 	Pieter Muntendam
					
	Title:	 	Vice-President R&D	 		 	Title:	 	President & CEO

  
 23 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit 1.12 
 Patent Rights 
 BG MEDICINE, INC. PATENT PORTFOLIO

 Exhibit 1.12 
  

											
	
DOCKET NO./TITLE OF CASE
	 	 U.S. PTO/STATUS
	 	 PCT/STATUS
	 	 EUROPE/STATUS
	 	 JAPAN/STATUS
	 	 OTHER COUNTRIES

						
	 [***]
	 	[***]	 	[***]	 		 		 	
						
	 [***]
	 	[***]	 		 		 		 	
						
	 [***]
	 	[***]	 		 		 		 	
						
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

									
	Pub. No.:	    	[***]	    	International Application No.:	    	[***]	  	
	Publication Date:	    	[***]	    	International Filing Date:	    	[***]	  	

  
 24 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	IPC:	    	[***]	  	
			
	Applicants:	    	[***]	  	
		    	[***]	  	
		    	[***]	  	
		    	[***]	  	
		    	[***]	  	
			
	Inventors:	    	[***]	  	
		    	[***]	  	
		    	[***]	  	
		    	[***]	  	
			
	Agent:	    	[***]	  	
		    	[***]	  	
			
	Priority Date:	    	[***]	  	
			
	Title:	    	[***]	  	
		    	[***]	  	

  
 25 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit 5.1 
 Clinical Studies and Clinical Indications 
 BGM use Commercially Reasonable Efforts
to perform the following activities in support of Galectin-3 clinical development. These activities shall be reviewed at the quarterly Steering Committee meetings and adjusted by mutual written agreement of the Parties. 

 

	 	1)	Conduct clinical studies and partnerships to confirm, extend and justify the use of Galectin-3 in the following areas. In addition, whenever possible provide sufficient
quantities of specimens from these studies to SIEMENS to allow for submission for additional clinical indications 

  

	 	a.	Heart Failure stratification: 

 Studies reasonably anticipated to show that Galectin-3 aids in the risk stratification of Heart Failure patients and provides additional clinical information versus other commonly used cardiac markers
such as BNP, and NT-BNP. 
  

	 	b.	Device Treatment Selection: 

 Studies reasonably anticipated to show the role of Galectin-3 in identifying responders for CRT or other device treatments in classes of patients that are not currently considered for these treatments.

  

	 	c.	Companion Diagnostic Studies: 

 Studies reasonably anticipated to show that current drugs, not commonly used, can be better selected and efficacious for patients using Galectin-3 levels. 

Studies reasonably anticipated to show that Galectin-3 may be useful in identifying heart failure patients for new drugs. 

 

	 	d.	Health Outcomes and Economic Studies: 

 Studies reasonably anticipated to show the outcome and economic benefit of using Galectin-3, for example, like the HUMANA study on the role of Galectin-3 measurements at admission in the active discharge
of HF patients. 
 Other studies or efforts for the marketing portion of the Product Fee. 

  
 26 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit 7.1 
 Target Development Plan and Timeline 
 SIEMENS will use Commercially Reasonable
Efforts to perform the following activities in support of Product development. These activities shall be reviewed at the quarterly Steering Committee meetings and adjusted by mutual written agreement of the Parties. 

 

	 	(a)	SIEMENS will initiate the [***] within [***] ([***]) days after agreement is reached pursuant to the preceding paragraph (a); 

 

	 	(b)	SIEMENS will use Commercially Reasonable Efforts to [***] 

  
 27 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit 12.12 
 Alternative Dispute Resolution 
 The Parties recognize that from
time to time a dispute may arise relating to any Party’s rights or obligations under this Agreement. The Parties agree that any such dispute shall be resolved by the Alternative Dispute Resolution (“ADR”) provisions set forth
in this Exhibit, the result of which shall be binding upon the Parties. 
 To begin the ADR process, a Party first must send
written notice of the dispute to the other Party for attempted resolution by good faith negotiations between their respective presidents (or their designees) of the affected subsidiaries, divisions, or business units within twenty-eight
(28) days after such notice is received (all references to “days” in this ADR provision are to calendar days). If the matter has not been resolved within twenty-eight (28) days after the notice of dispute, or if the Parties fail
to meet within such twenty-eight (28) days, either Party may initiate an ADR proceeding as provided herein. The Parties shall have the right to be represented by counsel in such a proceeding. 

1. To begin an ADR proceeding, a Party shall provide written notice to the other Party of the issues to be resolved by ADR. Within
fourteen (14) days after its receipt of such notice, the other Party may, by written notice to the Party initiating the ADR, add additional issues to be resolved within the same ADR. 

2. Within twenty-one (21) days following the initiation of the ADR proceeding, the Parties shall select a mutually acceptable
independent, impartial and conflicts-free neutral to preside in the resolution of any disputes in this ADR proceeding. If the Parties are unable to agree on a mutually acceptable neutral within such period, each Party will select one independent,
impartial and conflicts-free neutral and those two neutrals will select a third independent, impartial and conflicts-free neutral within ten (10) days thereafter. None of the neutrals selected may be current or former employees, officers,
directors, consultants or attorneys of any Party, its subsidiaries or Affiliates. 
 3. No earlier than twenty-eight
(28) days or later than fifty-six (56) days after selection, the neutral(s) shall hold a hearing to resolve each of the issues identified by the Parties. The ADR proceeding shall take place at a location agreed upon by the Parties. If the
Parties cannot agree, the neutral(s) shall designate a location other than the principal place of business of either Party or any of their subsidiaries or Affiliates. 
 4. At least seven (7) days prior to the hearing, each Party shall submit the following to the other Party and the neutral(s): 

(a) a copy of all exhibits on which such Party intends to rely in any oral or written presentation to the neutral;

 (b) a list of any witnesses such Party intends to call at the hearing, and a short summary of the anticipated
testimony of each witness; 

  
 28 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (c) a proposed ruling on each issue to be resolved, together with a request
for a specific damage award or other remedy for each issue. The proposed rulings and remedies shall not contain any recitation of the facts or any legal arguments and shall not exceed one (1) page per issue. The Parties agree that neither side
shall seek as part of its remedy any punitive damages. 
 (d) a brief in support of such Party’s proposed
rulings and remedies, provided that the brief shall not exceed twenty (20) pages, without agreement of the Parties. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding. 

Except as expressly set forth in subparagraphs 4(a) - 4(d), no discovery shall be required or permitted by any means,
including depositions, interrogatories, requests for admissions, or production of documents. 
 5. The hearing shall be
conducted on no more than three (3) consecutive days, as determined at least ten (10) days before the hearing by the neutral(s), and shall be governed by the following rules: 

(a) Each Party shall be entitled to no more than six (6) hours hearing time, as determined at least ten
(10) days before the hearing by the neutral(s), to present its case. The neutral(s) shall determine whether each Party has had the hours to which it is entitled. 

(b) Each Party shall be entitled, but not required, to make an opening statement, to present regular and rebuttal
testimony, documents or other evidence, to cross-examine witnesses, and to make a closing argument. Cross-examination of witnesses shall occur immediately after their direct testimony, and cross-examination time shall be charged against the party
conducting the cross-examination. 
 (c) The Party initiating the ADR shall begin the hearing and, if it chooses
to make an opening statement, shall address not only issues it raised but also any issues raised by the responding Party. The responding Party, if it chooses to make an opening statement, also shall address all issues raised in the ADR. Thereafter,
the presentation of regular and rebuttal testimony and documents, other evidence, and closing arguments shall proceed in the same sequence. 
 (d) Except when testifying, witnesses shall be excluded from the hearing until closing arguments. 
 (e) Settlement negotiations, including any statements made therein, shall not be admissible under any circumstances. Affidavits prepared for purposes of the ADR hearing also shall not be admissible. As to
all other matters, the neutral(s) shall have sole discretion regarding the admissibility of any evidence. 

  
 29 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 6. Within seven (7) days following completion of the hearing, each Party may submit to
the other Party and the neutral(s) a post-hearing brief in support of its proposed rulings and remedies, provided that such brief shall not contain or discuss any new evidence and shall not exceed ten (10) pages. This page limitation shall
apply regardless of the number of issues raised in the ADR proceeding. 
 7. The neutral(s) shall rule on each disputed issue
within fourteen (14) days following completion of the hearing. Such ruling shall adopt in its entirety the proposed ruling and remedy of one of the Parties on each disputed issue but may adopt one Party’s proposed rulings and remedies on
some issues and the other Party’s proposed rulings and remedies on other issues. The neutral(s) shall not issue any written opinion or otherwise explain the basis of the ruling. 

8. The neutral(s) shall be paid a reasonable fee plus expenses. These fees and expenses, along with the reasonable legal fees and
expenses of the prevailing Party (including all expert witness fees and expenses), the fees and expenses of a court reporter, and any expenses for a hearing room, shall be paid as follows: 

(a) If the neutral(s) rule(s) in favor of one Party(ies) on all disputed issues in the ADR, the losing Party(ies) shall
pay 100% of such fees and expenses. 
 (b) If the neutral(s) rule(s) in favor of one Party(ies) on some issues
and the other Party(ies) on other issues, the neutral(s) shall issue with the rulings a written determination as to how such fees and expenses shall be allocated between the Parties. The neutral(s) shall allocate fees and expenses in a way that
bears a reasonable relationship to the outcome of the ADR, with the Party(ies) prevailing on more issues, or on issues of greater value or gravity, recovering a relatively larger share of its (their) legal fees and expenses. 

9. The rulings of the neutral(s) and the allocation of fees and expenses shall be binding, non-reviewable, and non-appealable, and may be
entered as a final judgment in any court having jurisdiction. 
 10. Except as provided in paragraph 9 or as required by law,
the existence of the dispute, any settlement negotiations, the ADR hearing, any submissions (including exhibits, testimony, proposed rulings, and briefs), and the rulings shall be deemed Confidential Information. The neutral(s) shall have the
authority to impose sanctions for unauthorized disclosure of Confidential Information. 
 11. All ADR hearings shall be
conducted in the English language. 

  
 30 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit B 
 Specifications for Transfer of Cell Line 
 None. 

  
 31 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Schedule 8.2 
 Exceptions to Patent Representations and Warranties 
 None. 

  
 32 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.Unitil Corporation - Compensation of Directors

 Exhibit 10.21 

 
 UNITIL CORPORATION 

 
 Compensation of Directors 

 
 On December, 16, 2010, the Board of Directors of Unitil Corporation
(“Unitil”) approved and adopted a revised compensation arrangement for members of the Board of Directors. The compensation arrangement became effective on January 1, 2011. 
  
 The compensation arrangement applies to members of the Board of Directors who are not employees of Unitil or any of its
subsidiaries. The following table summarizes the material terms of the compensation arrangement. 
  

					
	 Category
	  	 Description
	  	 Amount

	 Board of Directors –

Annual Cash Retainer
	  	Each member of the Board of Directors will receive an annual cash retainer. Unitil will pay one-fourth of the annual cash retainer on the first business day of each fiscal
quarter.	  	$45,000 per year
			
	 Board of Directors –

Annual Equity Retainer
	  	Each member of the Board of Directors will receive an annual equity retainer. Unitil will issue the equity retainer on the first business day of October each year. In 2011, the
equity retainer will be in the form of Unitil’s common stock. Beginning in 2012, each member may elect to receive restricted stock units (with any phantom dividends reinvested in additional restricted stock units), in lieu of Unitil’s
common stock, as his or her annual equity retainer.	  	$20,500 per year (payable in kind as common stock or restricted stock units)
			
	 Board of Directors –

Special Meetings
	  	Each member of the Board of Directors will receive a fee for each special meeting of the Board of Directors that such member attends in person.	  	$2,000 per special meeting
			
	 Committees –

Annual Cash Retainer for Chair
	  	Each chair of a committee of the Board of Directors will receive an annual cash retainer. Unitil will pay one-fourth of the annual cash retainer on the first business day of each
fiscal quarter.	  	$8,000 per committee per year
			
	 Committees –

Annual Cash Retainer for Non-Chair Members
	  	Each non-chair member of a committee of the Board of Directors will receive an annual cash retainer. Unitil will pay one-fourth of the annual cash retainer on the first business
day of each fiscal quarter.	  	$3,000 per committee per year

  
 In addition, Unitil will reimburse each member of the Board of Directors for reasonable expenses that such member incurs in connection with attending meetings of the Board of Directors or committees
thereof.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}]]